

Judith Absalon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2917812/publications.pdf>

Version: 2024-02-01

15
papers

17,104
citations

687220

13
h-index

940416

16
g-index

18
all docs

18
docs citations

18
times ranked

25422
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older. <i>Vaccine</i> , 2022, 40, 1872-1878.	1.7	2
2	Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	14
3	Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 263-274.	4.6	70
4	Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. <i>New England Journal of Medicine</i> , 2021, 385, 239-250.	13.9	709
5	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. <i>New England Journal of Medicine</i> , 2021, 385, 1761-1773.	13.9	1,090
6	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. <i>New England Journal of Medicine</i> , 2020, 383, 2439-2450.	13.9	2,107
7	Phase III study of COVID-19 RNA vaccine BNT162b1 in adults. <i>Nature</i> , 2020, 586, 589-593.	13.7	1,197
8	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2020, 383, 2603-2615.	13.9	11,472
9	The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci. <i>Vaccine</i> , 2018, 36, 6867-6874.	1.7	29
10	From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine. <i>Expert Review of Vaccines</i> , 2018, 17, 461-477.	2.0	46
11	A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults. <i>New England Journal of Medicine</i> , 2017, 377, 2349-2362.	13.9	57
12	Safety of MenB-FHbp (Bivalent rLP2086), a Meningococcal Serogroup B Vaccine, in Young Adults: Results From a Phase 3 Trial. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
13	A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 673-682.	1.1	41
14	A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults. <i>Vaccine</i> , 2016, 34, 1465-1471.	1.7	26
15	Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 548-554.	1.1	39